Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso


Max is the Technology, Biopharma & Health Care Bureau Chief at Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

Will Obamacare Crush These Health Care Giants?

The uncertainty surrounding the Affordable Care Act looms large, but will managed care stocks like WellPoint and UnitedHealth continue to outperform the market?

What OncoMed's Deal With Celgene Means for Investors

A look at Celgene's latest deal with OncoMed, a small biotech that went public just a few months ago.

3 Drugs That Changed Medicine (and Were Discovered by Accident)

Pfizer and Allergan market game-changing drugs that were discovered by accident -- but how did it happen?

AstraZeneca Stock: 3 Things to Know

What should investors know about drugmaker AstraZeneca (NYSE: AZN) before buying or selling?

Teva Stock: 3 Key Things to Know

What key issues should investors look at when analyzing Teva's stock?

Motley Fool Co-Founder David Gardner on Investing for Beginners

One of our head Fools discusses why some people are fearful of managing their own money, and how The Motley Fool is helping.

Novo Nordisk's Biggest Strength and Weakness

Is Novo Nordisk's (NYSE: NVO) diabetes treatment-focused strategy wise, or should the company diversify?

Kickstarter and the "Long Tail"

Motley Fool co-founder David Gardner's thoughts on revolutionary platform Kickstarter.

How Investors Can Look Beyond the Numbers

Today’s business leaders lead lives that are public in ways we couldn’t have imagined 25 years ago, making investors’ job just a little easier.

3 Sources of Investment Ideas from Motley Fool Co-Founder David Gardner

David Gardner shares the three ways he becomes aware of new companies to research and potentially add to his portfolio.

"Invest in What You Know"? Maybe, Maybe Not.

David Gardner offers his thoughts on how to get your feet wet when investing in an unfamiliar industry.

Should You Fear Stocks in the Health-Care Space?

Motley Fool co-founder David Gardner discusses health-care stocks and two options for investors who fear them.

Motley Fool Co-Founder David Gardner's Approach to "Fearless" Investing

Motley Fool Co-Founder and Chief Rule Breaker David Gardner discusses his brand of "fearless" investing, how to look at stocks in the biotech industry, his investing philosophy -- and yes, even Kickstarter and the Pebble smartwatch.

Down 13%: More Bad Luck for Amarin Corporation plc

Shares of Amarin, which have already been crushed this month, dropped another 13% today. What was behind the plunge?

Down 8%: What's Behind Teva's Massive Plunge?

Teva Pharmaceuticals is down 8% today, but it's not directly due to competition in the multiple sclerosis space from new drugs like Biogen's Tecfidera. To find out what happened and what may lie ahead for Teva, watch this video.

Another Big Win for Big Biotech Biogen?

Biogen reported its third-quarter results, but was it all good news for the big biotech company?

Why This Dow Heavyweight Sank on Earnings

Why did shares of Dow component Merck drop as other drugmakers, such as Bristol-Myers Squibb and AstraZeneca, rose today?

What Was Behind Ariad's 40% Drop?

Ariad Pharmaceuticals has already dropped significantly this week --- what was behind today's move?

What Was Behind Anacor's 28% Climb?

Why did shares of biotech company Anacor surge today?

The Next Cholesterol-Fighting Blockbuster Drug?

Regeneron and its partner Sanofi reported results from a late-stage trial for their new cholesterol-lowering drug. Can this be the next Lipitor?